GB0328363D0
(en)
*
|
2003-12-06 |
2004-01-14 |
Imp College Innovations Ltd |
Therapeutically useful molecules
|
US7994298B2
(en)
|
2004-09-24 |
2011-08-09 |
Trustees Of Dartmouth College |
Chimeric NK receptor and methods for treating cancer
|
KR101130597B1
(en)
|
2005-09-13 |
2012-04-02 |
다카라 바이오 가부시키가이샤 |
T-cell receptor and nucleic acid encoding the receptor
|
IL286053B2
(en)
|
2005-10-18 |
2023-03-01 |
Nat Jewish Health |
Process of preparing red blood cells using conditionally immortalized long-term hematopoietic stem cells and erythropoietin
|
WO2008039694A2
(en)
*
|
2006-09-26 |
2008-04-03 |
St. Jude Children's Research Hospital |
Methods and compositions for monitoring t cell receptor diversity
|
US8088379B2
(en)
*
|
2006-09-26 |
2012-01-03 |
The United States Of America As Represented By The Department Of Health And Human Services |
Modified T cell receptors and related materials and methods
|
EP2087000A2
(en)
*
|
2006-09-29 |
2009-08-12 |
Immunocore Ltd. |
T cell therapies
|
US8119772B2
(en)
|
2006-09-29 |
2012-02-21 |
California Institute Of Technology |
MART-1 T cell receptors
|
WO2009042570A2
(en)
*
|
2007-09-25 |
2009-04-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Modified t cell receptors and related materials and methods
|
KR20170078862A
(en)
|
2008-05-16 |
2017-07-07 |
타이가 바이오테크놀로지스, 인코포레이티드 |
Antibodies and processes for preparing the same
|
EP3916010A1
(en)
|
2008-08-28 |
2021-12-01 |
Taiga Biotechnologies, Inc. |
Modulators of myc, methods of using the same and methods of identifying agents that modulate myc
|
GB0911566D0
(en)
|
2009-07-03 |
2009-08-12 |
Immunocore Ltd |
T cell receptors
|
US9273283B2
(en)
|
2009-10-29 |
2016-03-01 |
The Trustees Of Dartmouth College |
Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
|
US9181527B2
(en)
|
2009-10-29 |
2015-11-10 |
The Trustees Of Dartmouth College |
T cell receptor-deficient T cell compositions
|
WO2012013913A1
(en)
|
2010-07-28 |
2012-02-02 |
Immunocore Ltd |
T cell receptors
|
US9833476B2
(en)
|
2011-08-31 |
2017-12-05 |
The Trustees Of Dartmouth College |
NKP30 receptor targeted therapeutics
|
WO2013169691A1
(en)
|
2012-05-07 |
2013-11-14 |
Trustees Of Dartmouth College |
Anti-b7-h6 antibody, fusion proteins, and methods of using the same
|
EP3868387A1
(en)
|
2012-07-20 |
2021-08-25 |
Taiga Biotechnologies, Inc. |
Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
|
US10272115B2
(en)
|
2013-03-11 |
2019-04-30 |
Taiga Biotechnologies, Inc. |
Production and use of red blood cells
|
GB201309421D0
(en)
|
2013-05-24 |
2013-07-10 |
Imp Innovations Ltd |
Polypeptides
|
GB201313377D0
(en)
|
2013-07-26 |
2013-09-11 |
Adaptimmune Ltd |
T cell receptors
|
SG10201803533YA
(en)
|
2013-10-31 |
2018-06-28 |
Hutchinson Fred Cancer Res |
Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
|
US10801070B2
(en)
|
2013-11-25 |
2020-10-13 |
The Broad Institute, Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer
|
US11725237B2
(en)
|
2013-12-05 |
2023-08-15 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
CN106456724A
(en)
|
2013-12-20 |
2017-02-22 |
博德研究所 |
Combination therapy with neoantigen vaccine
|
SG10201804439PA
(en)
|
2013-12-20 |
2018-06-28 |
Hutchinson Fred Cancer Res |
Tagged chimeric effector molecules and receptors thereof
|
CA2939093A1
(en)
|
2014-02-14 |
2015-08-20 |
Immune Design Corp. |
Immunotherapy of cancer through combination of local and systemic immune stimulation
|
KR102290829B1
(en)
*
|
2014-03-14 |
2021-08-18 |
이뮤노코어 리미티드 |
Tcr libraries
|
US10202640B2
(en)
*
|
2014-05-07 |
2019-02-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Single cell analysis of T cells using high-throughput multiplex amplification and deep sequencing
|
EP3172325B1
(en)
|
2014-07-22 |
2023-06-28 |
The University of Notre Dame du Lac |
Molecular constructs and uses thereof
|
CA2967073A1
(en)
*
|
2014-11-07 |
2016-05-12 |
Guangzhou Xiangxue Pharmaceutical Co. Ltd |
Soluble heterodimeric t cell receptor, and preparation method and use thereof
|
GB201421096D0
(en)
|
2014-11-27 |
2015-01-14 |
Imp Innovations Ltd |
Genome editing methods
|
EP3234130B1
(en)
|
2014-12-19 |
2020-11-25 |
The Broad Institute, Inc. |
Methods for profiling the t-cell- receptor repertoire
|
EP3234193B1
(en)
|
2014-12-19 |
2020-07-15 |
Massachusetts Institute of Technology |
Molecular biomarkers for cancer immunotherapy
|
JP6917896B2
(en)
|
2015-03-05 |
2021-08-18 |
フレッド ハッチンソン キャンサー リサーチ センター |
Immunomodulatory fusion proteins and their use
|
EP3288570A4
(en)
|
2015-04-29 |
2018-11-21 |
Fred Hutchinson Cancer Research Center |
Modified stem cells and uses thereof
|
WO2016176651A2
(en)
|
2015-04-29 |
2016-11-03 |
Fred Hutchinson Cancer Research Center |
Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
|
TWI806815B
(en)
|
2015-05-20 |
2023-07-01 |
美商博德研究所有限公司 |
Shared gata3-related tumor-specific neoantigens
|
WO2016205749A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
GB201516265D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
GB201516275D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
GB201516269D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
GB201516274D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
GB201516277D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR libraries
|
GB201516272D0
(en)
*
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
GB201516270D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
US20190255107A1
(en)
|
2015-10-09 |
2019-08-22 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
WO2017075478A2
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
|
WO2017087708A1
(en)
|
2015-11-19 |
2017-05-26 |
The Brigham And Women's Hospital, Inc. |
Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
|
CN116082505A
(en)
|
2016-02-25 |
2023-05-09 |
细胞医学公司 |
Binding members for PD-L1
|
US10982136B2
(en)
|
2016-02-26 |
2021-04-20 |
The Regents Of The University Of California |
Ligand-sensitized lanthanide nanocrystals as ultraviolet downconverters
|
RU2018138122A
(en)
|
2016-04-05 |
2020-05-12 |
Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
NEW THERAPY
|
KR102542533B1
(en)
|
2016-04-14 |
2023-06-13 |
프레드 허친슨 캔서 센터 |
Compositions and methods for programming therapeutic cells using targeting nucleic acid nanotransporters
|
WO2017184590A1
(en)
|
2016-04-18 |
2017-10-26 |
The Broad Institute Inc. |
Improved hla epitope prediction
|
IL262772B2
(en)
|
2016-05-06 |
2023-10-01 |
Juno Therapeutics Inc |
Genetically engineered cells and methods of making the same
|
MA45491A
(en)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics Inc |
CMH-E RESTRICTED EPITOPES, BINDING MOLECULES AND RELATED METHODS AND USES
|
CN110291402B
(en)
|
2016-06-27 |
2023-09-01 |
朱诺治疗学股份有限公司 |
Method for identifying peptide epitopes, molecules binding such epitopes and related uses
|
JP2019532017A
(en)
|
2016-07-14 |
2019-11-07 |
フレッド ハッチンソン キャンサー リサーチ センター |
Multiple bispecific binding domain constructs exhibiting different epitope binding for treating cancer
|
WO2018035364A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute Inc. |
Product and methods useful for modulating and evaluating immune responses
|
US11235076B2
(en)
|
2016-08-29 |
2022-02-01 |
Fred Hutchinson Cancer Research Center |
Chelating platform for delivery of radionuclides
|
DK3509595T3
(en)
|
2016-09-06 |
2023-01-23 |
Univ California |
Formulations of hydroxypyridonate actinide/lanthanide decorporating agents
|
US20190262399A1
(en)
|
2016-09-07 |
2019-08-29 |
The Broad Institute, Inc. |
Compositions and methods for evaluating and modulating immune responses
|
CN110139873A
(en)
|
2016-10-03 |
2019-08-16 |
朱诺治疗学股份有限公司 |
HPV specific binding molecules
|
US20200016202A1
(en)
|
2016-10-07 |
2020-01-16 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
ES2939646T3
(en)
|
2016-10-13 |
2023-04-25 |
Juno Therapeutics Inc |
Immunotherapy methods and compositions comprising modulators of the tryptophan metabolic pathway
|
WO2018093591A1
(en)
|
2016-11-03 |
2018-05-24 |
Juno Therapeutics, Inc. |
Combination therapy of a cell based therapy and a microglia inhibitor
|
CA3042049A1
(en)
|
2016-11-03 |
2018-05-11 |
Juno Therapeutics, Inc. |
Combination therapy of a t cell therapy and a btk inhibitor
|
CN113786476A
(en)
|
2016-12-02 |
2021-12-14 |
泰加生物工艺学公司 |
Nanoparticle formulations
|
MX2019006285A
(en)
|
2016-12-03 |
2019-12-16 |
Juno Therapeutics Inc |
Methods for modulation of car-t cells.
|
MA46963A
(en)
|
2016-12-03 |
2019-10-09 |
Juno Therapeutics Inc |
METHODS FOR DETERMINING THE DOSAGE OF CAR-T CELLS
|
CN110249046A
(en)
|
2016-12-05 |
2019-09-17 |
朱诺治疗学股份有限公司 |
The generation of engineering cell for adoptive cellular therapy
|
IL310711A
(en)
|
2017-01-10 |
2024-04-01 |
Intrexon Corp |
Modulating expression of polypeptides via new gene switch expression systems
|
CN110691792A
(en)
|
2017-01-10 |
2020-01-14 |
朱诺治疗学股份有限公司 |
Epigenetic analysis of cell therapies and related methods
|
WO2018132739A2
(en)
|
2017-01-13 |
2018-07-19 |
Agenus Inc. |
T cell receptors that bind to ny-eso-1 and methods of use thereof
|
CA3050085A1
(en)
|
2017-01-20 |
2018-07-26 |
Juno Therapeutics Gmbh |
Cell surface conjugates and related cell compositions and methods
|
US11549149B2
(en)
|
2017-01-24 |
2023-01-10 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
SI3580561T1
(en)
|
2017-02-12 |
2024-04-30 |
Biontech Us Inc. |
Hla-based methods and compositions and uses thereof
|
EP4269594A3
(en)
|
2017-02-17 |
2023-12-20 |
Fred Hutchinson Cancer Center |
Combination therapies for treatment of bcma-related cancers and autoimmune disorders
|
MX2019010171A
(en)
|
2017-02-27 |
2019-10-15 |
Juno Therapeutics Inc |
Compositions, articles of manufacture and methods related to dosing in cell therapy.
|
IL292352B2
(en)
|
2017-03-14 |
2024-03-01 |
Juno Therapeutics Inc |
Methods for cryogenic storage
|
CA3055784A1
(en)
|
2017-03-17 |
2018-09-20 |
Fred Hutchinson Cancer Research Center |
Immunomodulatory fusion proteins and uses thereof
|
WO2018183908A1
(en)
|
2017-03-31 |
2018-10-04 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ovarian tumors
|
WO2018183921A1
(en)
|
2017-04-01 |
2018-10-04 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
WO2018187791A1
(en)
|
2017-04-07 |
2018-10-11 |
Juno Therapeutics, Inc |
Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
|
WO2018191553A1
(en)
|
2017-04-12 |
2018-10-18 |
Massachusetts Eye And Ear Infirmary |
Tumor signature for metastasis, compositions of matter methods of use thereof
|
MX2019012189A
(en)
|
2017-04-14 |
2020-12-10 |
Juno Therapeutics Inc |
Methods for assessing cell surface glycosylation.
|
MX2019012398A
(en)
|
2017-04-18 |
2020-09-25 |
Broad Inst Inc |
Compositions for detecting secretion and methods of use.
|
IL310031A
(en)
|
2017-05-01 |
2024-03-01 |
Juno Therapeutics Inc |
Combination of a cell therapy and an immunomodulatory compound
|
WO2018211115A1
(en)
|
2017-05-18 |
2018-11-22 |
Umc Utrecht Holding B.V. |
Compositions and methods for cell targeting therapies
|
AU2018275891A1
(en)
|
2017-06-02 |
2019-12-12 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods related to toxicity associated with cell therapy
|
AU2018275894A1
(en)
|
2017-06-02 |
2019-12-12 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods for treatment using adoptive cell therapy
|
IL270990B2
(en)
|
2017-06-07 |
2024-02-01 |
Precigen Inc |
Expression of novel cell tags
|
EP3638218A4
(en)
|
2017-06-14 |
2021-06-09 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
GB201709866D0
(en)
|
2017-06-20 |
2017-08-02 |
Immunocore Ltd |
T cell receptors
|
JP2020526194A
(en)
|
2017-06-29 |
2020-08-31 |
ジュノー セラピューティクス インコーポレイテッド |
Mouse model for assessing toxicity associated with immunotherapeutic agents
|
JP7337773B2
(en)
|
2017-07-29 |
2023-09-04 |
ジュノー セラピューティクス インコーポレイテッド |
Reagents for expanding cells expressing recombinant receptors
|
SG11202000612TA
(en)
|
2017-08-03 |
2020-02-27 |
Taiga Biotechnologies Inc |
Methods and compositions for the treatment of melanoma
|
US10149898B2
(en)
|
2017-08-03 |
2018-12-11 |
Taiga Biotechnologies, Inc. |
Methods and compositions for the treatment of melanoma
|
WO2019032927A1
(en)
|
2017-08-09 |
2019-02-14 |
Juno Therapeutics, Inc. |
Methods for producing genetically engineered cell compositions and related compositions
|
CA3070575A1
(en)
|
2017-08-09 |
2019-02-14 |
Juno Therapeutics, Inc. |
Methods and compositions for preparing genetically engineered cells
|
EP3441461A1
(en)
|
2017-08-11 |
2019-02-13 |
Baylor College of Medicine |
Cd1d-restricted nkt cells as a platform for off-the-shelf cancer immunotherapy
|
MA50057A
(en)
|
2017-09-01 |
2020-07-08 |
Juno Therapeutics Inc |
GENE EXPRESSION AND ASSESSMENT OF A RISK OF DEVELOPING TOXICITY FOLLOWING CELL THERAPY
|
KR20200052327A
(en)
|
2017-09-04 |
2020-05-14 |
아게누스 인코포레이티드 |
T cell receptor binding to mixed lineage leukemia (MLL) -specific phosphopeptides and methods of use thereof
|
WO2019051335A1
(en)
|
2017-09-07 |
2019-03-14 |
Juno Therapeutics, Inc. |
Methods of identifying cellular attributes related to outcomes associated with cell therapy
|
CN111511388A
(en)
|
2017-09-21 |
2020-08-07 |
博德研究所 |
Systems, methods, and compositions for targeted nucleic acid editing
|
WO2019070541A1
(en)
|
2017-10-03 |
2019-04-11 |
Juno Therapeutics, Inc. |
Hpv-specific binding molecules
|
EP3692058A1
(en)
|
2017-10-06 |
2020-08-12 |
Oslo Universitetssykehus HF |
Chimeric antigen receptors
|
US11732257B2
(en)
|
2017-10-23 |
2023-08-22 |
Massachusetts Institute Of Technology |
Single cell sequencing libraries of genomic transcript regions of interest in proximity to barcodes, and genotyping of said libraries
|
US11851679B2
(en)
|
2017-11-01 |
2023-12-26 |
Juno Therapeutics, Inc. |
Method of assessing activity of recombinant antigen receptors
|
CA3084514A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Process for generating therapeutic compositions of engineered cells
|
WO2019089858A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
AU2018360801A1
(en)
|
2017-11-01 |
2020-05-14 |
Celgene Corporation |
Process for producing a T cell composition
|
US11564946B2
(en)
|
2017-11-01 |
2023-01-31 |
Juno Therapeutics, Inc. |
Methods associated with tumor burden for assessing response to a cell therapy
|
CA3081456A1
(en)
|
2017-11-01 |
2019-05-09 |
Editas Medicine, Inc. |
Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
|
JP2021502077A
(en)
|
2017-11-06 |
2021-01-28 |
エディタス・メディシン,インコーポレイテッド |
Methods, compositions and components for CRISPR-CAS9 editing of CBLB on T cells for immunotherapy
|
EP3706754A1
(en)
|
2017-11-06 |
2020-09-16 |
Juno Therapeutics, Inc. |
Combination of a cell therapy and a gamma secretase inhibitor
|
WO2019094983A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
|
JP2021503885A
(en)
|
2017-11-22 |
2021-02-15 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
Expanded culture of peripheral blood lymphocytes (PBL) from peripheral blood
|
EP3716980A1
(en)
|
2017-12-01 |
2020-10-07 |
Juno Therapeutics, Inc. |
Methods for dosing and for modulation of genetically engineered cells
|
WO2019113556A1
(en)
|
2017-12-08 |
2019-06-13 |
Juno Therapeutics, Inc. |
Serum-free media formulation for culturing cells and methods of use thereof
|
EP3720480A2
(en)
|
2017-12-08 |
2020-10-14 |
Juno Therapeutics, Inc. |
Phenotypic markers for cell therapy and related methods
|
SG11202005272SA
(en)
|
2017-12-08 |
2020-07-29 |
Juno Therapeutics Inc |
Process for producing a composition of engineered t cells
|
US11994512B2
(en)
|
2018-01-04 |
2024-05-28 |
Massachusetts Institute Of Technology |
Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
|
CN111971059A
(en)
|
2018-01-31 |
2020-11-20 |
细胞基因公司 |
Combination therapy using adoptive cell therapy and checkpoint inhibitors
|
JP2021520211A
(en)
|
2018-04-05 |
2021-08-19 |
ジュノー セラピューティクス インコーポレイテッド |
T cells expressing recombinant receptors, related polynucleotides, and methods
|
CA3094468A1
(en)
|
2018-04-05 |
2019-10-10 |
Juno Therapeutics, Inc. |
Methods of producing cells expressing a recombinant receptor and related compositions
|
MX2020010460A
(en)
|
2018-04-05 |
2021-01-29 |
Juno Therapeutics Inc |
T cell receptors and engineered cells expressing same.
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
BR112020023195A2
(en)
|
2018-05-14 |
2021-09-28 |
Immunocore Limited |
BIFUNCTIONAL BINDING POLYPEPTIDES, PHARMACEUTICAL COMPOSITION, NUCLEIC ACID, EXPRESSION VECTOR, HOST CELL, METHOD TO PREPARE THE BIFUNCTIONAL BINDING POLYPEPTIDE, AND METHOD TO TREAT AN AUTOIMMUNE DISORDER
|
WO2019219979A1
(en)
|
2018-05-18 |
2019-11-21 |
Umc Utrecht Holding B.V. |
Compositions and methods for cell targeting therapies
|
WO2019232542A2
(en)
|
2018-06-01 |
2019-12-05 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
US11845797B2
(en)
|
2018-07-03 |
2023-12-19 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
EP3833759A1
(en)
|
2018-08-09 |
2021-06-16 |
Juno Therapeutics, Inc. |
Methods for assessing integrated nucleic acids
|
BR112021002390A2
(en)
|
2018-08-09 |
2021-05-11 |
Juno Therapeutics Inc |
processes to generate modified cells and their compositions
|
WO2020068304A2
(en)
|
2018-08-20 |
2020-04-02 |
The Broad Institute, Inc. |
Inhibitors of rna-guided nuclease target binding and uses thereof
|
US20210324357A1
(en)
|
2018-08-20 |
2021-10-21 |
The Brigham And Women's Hospital, Inc. |
Degradation domain modifications for spatio-temporal control of rna-guided nucleases
|
US20210355522A1
(en)
|
2018-08-20 |
2021-11-18 |
The Broad Institute, Inc. |
Inhibitors of rna-guided nuclease activity and uses thereof
|
WO2020049496A1
(en)
|
2018-09-05 |
2020-03-12 |
Glaxosmithkline Intellectual Property Development Limited |
T cell modification
|
EP3850366A1
(en)
|
2018-09-11 |
2021-07-21 |
Juno Therapeutics, Inc. |
Methods for mass spectrometry analysis of engineered cell compositions
|
EP4268831A3
(en)
|
2018-09-12 |
2024-05-22 |
Fred Hutchinson Cancer Center |
Reducing cd33 expression to selectively protect therapeutic cells
|
US20210382068A1
(en)
|
2018-10-02 |
2021-12-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
US20210379057A1
(en)
|
2018-10-16 |
2021-12-09 |
Massachusetts Institute Of Technology |
Nutlin-3a for use in treating a mycobacterium tuberculosis infection
|
US20220170097A1
(en)
|
2018-10-29 |
2022-06-02 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
BR112021008133A2
(en)
|
2018-10-31 |
2021-10-05 |
Juno Therapeutics Gmbh |
METHODS FOR SELECTION AND STIMULATION OF CELLS AND DEVICES FOR THE SAME
|
US20210393691A1
(en)
|
2018-11-06 |
2021-12-23 |
Juno Therapeutics, Inc. |
Process for producing genetically engineered t cells
|
CA3117978A1
(en)
|
2018-11-08 |
2020-05-14 |
Juno Therapeutics, Inc. |
Methods and combinations for treatment and t cell modulation
|
KR20210110811A
(en)
|
2018-11-30 |
2021-09-09 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Methods of dosing and treatment of B-cell malignancies in adoptive cell therapy
|
AU2019387497A1
(en)
|
2018-11-30 |
2021-06-24 |
Juno Therapeutics, Inc. |
Methods for treatment using adoptive cell therapy
|
US20220062394A1
(en)
|
2018-12-17 |
2022-03-03 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
CN113474840A
(en)
|
2018-12-21 |
2021-10-01 |
百欧恩泰美国公司 |
Methods and systems for predicting HLA class II specific epitopes and characterizing CD4+ T cells
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
GB201901306D0
(en)
|
2019-01-30 |
2019-03-20 |
Immunocore Ltd |
Multi-domain binding molecules
|
GB201901305D0
(en)
|
2019-01-30 |
2019-03-20 |
Immunocore Ltd |
Specific binding molecules
|
EP3931310A1
(en)
|
2019-03-01 |
2022-01-05 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
US20220154282A1
(en)
|
2019-03-12 |
2022-05-19 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
EP3942023A1
(en)
|
2019-03-18 |
2022-01-26 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
GB201904328D0
(en)
|
2019-03-28 |
2019-05-15 |
Immunocore Ltd |
Specific binding molecules
|
KR20220016475A
(en)
|
2019-05-01 |
2022-02-09 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Cells, Associated Polynucleotides and Methods Expressing Recombinant Receptors at the Modified TFTFR2 Locus
|
WO2020236967A1
(en)
|
2019-05-20 |
2020-11-26 |
The Broad Institute, Inc. |
Random crispr-cas deletion mutant
|
WO2020243371A1
(en)
|
2019-05-28 |
2020-12-03 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating immune responses
|
AU2020287882A1
(en)
|
2019-06-07 |
2022-01-20 |
Juno Therapeutics, Inc. |
Automated T cell culture
|
CA3142361A1
(en)
|
2019-06-12 |
2020-12-17 |
Juno Therapeutics, Inc. |
Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein
|
CA3138188A1
(en)
|
2019-07-02 |
2021-01-07 |
Fred Hutchinson Cancer Research Center |
Recombinant ad35 vectors and related gene therapy improvements
|
US20220282333A1
(en)
|
2019-08-13 |
2022-09-08 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
CN114555112A
(en)
|
2019-08-22 |
2022-05-27 |
朱诺治疗学股份有限公司 |
Combination therapy of T cell therapy and ZESTE enhancer homolog 2(EZH2) inhibitors and related methods
|
US20220298501A1
(en)
|
2019-08-30 |
2022-09-22 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
JP2023500318A
(en)
|
2019-10-30 |
2023-01-05 |
ジュノ セラピューティクス ゲーエムベーハー |
Cell selection and/or cell stimulation devices and methods of use
|
EP4289951A3
(en)
|
2019-12-04 |
2024-03-13 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
CN115398231A
(en)
|
2019-12-06 |
2022-11-25 |
朱诺治疗学股份有限公司 |
Methods related to toxicity and response associated with cell therapy for treatment of B cell malignancies
|
US11865168B2
(en)
|
2019-12-30 |
2024-01-09 |
Massachusetts Institute Of Technology |
Compositions and methods for treating bacterial infections
|
WO2021154887A1
(en)
|
2020-01-28 |
2021-08-05 |
Juno Therapeutics, Inc. |
Methods for t cell transduction
|
CN115087489A
(en)
|
2020-02-14 |
2022-09-20 |
艾达普特免疫有限公司 |
Method for treating cancer or tumor
|
WO2021189059A2
(en)
|
2020-03-20 |
2021-09-23 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
US20210322471A1
(en)
|
2020-03-27 |
2021-10-21 |
Dcprime B.V. |
In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
WO2021191870A1
(en)
|
2020-03-27 |
2021-09-30 |
Dcprime B.V. |
Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
EP4126924A4
(en)
*
|
2020-03-27 |
2024-04-24 |
2Seventy Bio Inc |
T cell receptors
|
EP4150640A1
(en)
|
2020-05-13 |
2023-03-22 |
Juno Therapeutics, Inc. |
Methods of identifying features associated with clinical response and uses thereof
|
WO2021231661A2
(en)
|
2020-05-13 |
2021-11-18 |
Juno Therapeutics, Inc. |
Process for producing donor-batched cells expressing a recombinant receptor
|
JP2023531531A
(en)
|
2020-06-26 |
2023-07-24 |
ジュノ セラピューティクス ゲーエムベーハー |
Engineered T Cells Conditionally Expressing Recombinant Receptors, Related Polynucleotides, and Methods
|
WO2022060904A1
(en)
|
2020-09-16 |
2022-03-24 |
Obsidian Therapeutics, Inc. |
Compositions and methods for expression of t-cell receptors with small molecule-regulated cd40l in t cells
|
EP4240405A1
(en)
|
2020-11-05 |
2023-09-13 |
Mendus B.V. |
Use of tumor-independent antigens in immunotherapies
|
KR20230112654A
(en)
|
2020-11-24 |
2023-07-27 |
상하이 젠베이스 바이오테크놀로지 씨오., 엘티디. |
T cell receptor recognizing RAS mutant epitope peptides and RAS mutants
|
WO2022133030A1
(en)
|
2020-12-16 |
2022-06-23 |
Juno Therapeutics, Inc. |
Combination therapy of a cell therapy and a bcl2 inhibitor
|
CN116867799A
(en)
|
2021-02-10 |
2023-10-10 |
上海吉倍生物技术有限公司 |
Ras G13D mutant epitope peptide and T cell receptor for recognizing Ras G13D mutant
|
WO2022183167A1
(en)
|
2021-02-25 |
2022-09-01 |
Alaunos Therapeutics, Inc. |
Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
|
US20240150711A1
(en)
|
2021-03-01 |
2024-05-09 |
Dana-Farber Cancer Institute, Inc. |
Personalized redirection and reprogramming of t cells for precise targeting of tumors
|
WO2022187406A1
(en)
|
2021-03-03 |
2022-09-09 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and a dgk inhibitor
|
KR20230159851A
(en)
|
2021-03-22 |
2023-11-22 |
주노 쎄러퓨티크스 인코퍼레이티드 |
How to Determine the Potency of a Therapeutic Cell Composition
|
KR20240005700A
(en)
|
2021-03-29 |
2024-01-12 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Dosing and Treatment Methods Using Combination of Checkpoint Inhibitor Therapy and CAR T Cell Therapy
|
JP2024517863A
(en)
|
2021-05-06 |
2024-04-23 |
ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
Methods for stimulating and transducing cells
|
BR112023025515A2
(en)
|
2021-06-10 |
2024-02-27 |
Orna Therapeutics Inc |
CIRCULAR RNA COMPOSITIONS AND METHODS
|
TW202322851A
(en)
|
2021-09-30 |
2023-06-16 |
美商歐納醫療公司 |
Lipid nanoparticle compositions for delivering circular polynucleotides
|
TW202334080A
(en)
|
2021-11-08 |
2023-09-01 |
美商歐納醫療公司 |
Lipid nanoparticle compositions for delivering circular polynucleotides
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
WO2023147515A1
(en)
|
2022-01-28 |
2023-08-03 |
Juno Therapeutics, Inc. |
Methods of manufacturing cellular compositions
|
WO2023150562A1
(en)
|
2022-02-01 |
2023-08-10 |
Alaunos Therapeutics, Inc. |
Methods for activation and expansion of t cells
|
WO2023196884A1
(en)
|
2022-04-06 |
2023-10-12 |
Juno Therapeutics, Inc. |
Detection assay for human papillomavirus (hpv) type 16 (hpv-16)
|
WO2023213969A1
(en)
|
2022-05-05 |
2023-11-09 |
Juno Therapeutics Gmbh |
Viral-binding protein and related reagents, articles, and methods of use
|
US20240002800A1
(en)
|
2022-05-16 |
2024-01-04 |
Mendus B.V. |
Use of leukemia-derived cells for enhancing natural killer (nk) cell therapy
|
WO2023230548A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
US20240052049A1
(en)
|
2022-06-24 |
2024-02-15 |
Orna Therapeutics, Inc. |
Circular rna encoding chimeric antigen receptors targeting bcma
|
WO2024006960A1
(en)
|
2022-06-29 |
2024-01-04 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids
|
WO2024038198A1
(en)
|
2022-08-18 |
2024-02-22 |
Immunocore Limited |
Multi-domain binding molecules
|
WO2024038183A1
(en)
|
2022-08-18 |
2024-02-22 |
Immunocore Limited |
Multi-domain binding molecules
|
WO2024038193A1
(en)
|
2022-08-18 |
2024-02-22 |
Immunocore Limited |
Multi-domain binding molecules
|
WO2024054944A1
(en)
|
2022-09-08 |
2024-03-14 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|
WO2024098024A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
WO2024102730A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and nanoparticle compositions for delivering polynucleotides
|
WO2024100604A1
(en)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Methods for manufacturing engineered immune cells
|